Home › Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS
 

Keywords :   


Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS

2015-03-04 05:59:44| drugdiscoveryonline Home Page

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS)

Tags: development process publication drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
17.05Eastern North Pacific Tropical Weather Outlook
17.05Boeing boss's $33m pay package approved
More »